SLC5A2 and heart failure: Studies investigating SGLT2 inhibitors in patients with heart failure with reduced ejection fraction (with and without T2D) have also recently reported numerical and substantial reductions in renal composite outcomes compared with placebo [dapagliflozin: HR: 0.71; 95% CI 0.44, 1.16 (eGFR < 50%, ESKD, or renal death) [48]; empagliflozin: HR: 0.50; 95% CI 0.32, 0.77 (eGFR < 50% or ESKD)] [49].